A Phase 3 interventional study of MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA) and Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China) in Meningococcal Infection and Healthy Volunteers, sponsored by Sanofi. Recruiting at 8 sites in China. Open to participants aged 2 Months to 23 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Sanofi · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies in Meningococcal Infections by Sanofi — 2 open to participants now, 2 under way, 1 of them phase 3. Meningococcal Infections · Sanofi.
Among the 57 studies in Meningococcal Infections by Sanofi, this one has the largest planned enrollment of the 51 interventional ones that give a count, is the only one that started in 2026, is one of 25 in phase 3, and was the 57th registered.
243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.
Browse Meningococcal Infections studies →2 of the 57 studies in Meningococcal Infections by Sanofi are open now, in 2 countries. Recruiting first, the newest first:
Sanofi Pasteur, a Sanofi Company · Sites in United States
Healthy volunteers
By country, each count listing its studies:
Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.
This study: 2 Months to 23 Months · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 17 · Phase 3 25 · Phase 4 8
First in 2002; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 4,568 is above the median of 456 across 214 interventional studies indexed under Meningococcal Infections.
Median enrollment 378 across the 51 interventional studies, 440 across the 6 observational. Of the 55 that completed or were terminated, 51 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
Sanofi is the lead sponsor of 1,560 studies on the registry; 90 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 57 studies in Meningococcal Infections by Sanofi, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to describe the safety and immunogenicity of MenACYW conjugate vaccine compared with locally-licensed meningococcal vaccines in healthy infants and toddlers in China.
Study details include:
Two blood samples are collected pre-vaccination (D01) and 30 days post the 2nd dose of vaccination (D61 or D121). Telephone calls (TCs) are planned on the 4th, the 9th, and the 21st day after each vaccination, and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit for safety follow-up. For participants receiving the second vaccination with a 3-month interval: an on-site visit is planned 30 days post the 1st dose of vaccination (V02, D31) for participant diary collection.
- Cohort II (Groups 3 and 4): a 2-dose vaccination at V01 (D01) and V02 (D31) or V03 (D91). A 1-dose booster is planned for Group 3 only at 18 MoA (within the 18th month from the participant's birth date).
Up to 4 blood samples will be collected. In the primary vaccination period, blood samples are collected before the first primary vaccination (D01) and 30 days post the 2nd dose of primary vaccination (D61 or D121). A blood sample will be collected from all participants at 18 MoA. A post-booster blood sample will be collected from participants in Group 3, 30 days post their booster vaccination.
Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods, respectively, for safety follow-up.
For participants receiving the second vaccination with a 3-month interval: an on-site visit is planned 30 days post the 1st dose of vaccination (V02, D31) for participant diary collection.
- Cohort III - Groups 5 and 6: a 3-dose primary vaccination at V01 (D01), V02 (D31) and V03 (D61), a 1-dose booster at 12 MoA (within the 12th months from the participant's birth date) on V05 or at 18 MoA (within the 18th months from the participant's birth date) on V06.
In total 4 blood samples are to be collected. In the primary vaccination period, blood samples are to be collected before the first primary vaccination (D01) and 30 days post the 3rd dose of primary vaccination (D91); in the booster vaccination period, blood samples are to be collected before booster vaccination at V05 (for participants receiving the booster at 12 MoA) or V06 (for participants receiving the booster at 18 MoA), and 30 days post booster vaccination (V05 + 30 days or V06 + 30 days).
Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods respectively for safety follow-up.
- Cohort III - Group 7: a 3-dose primary vaccination at V01 (D01), V02 (D61) and V03 (D121), a 1-dose booster at V05 at 12 MoA (within the 12th months from the participant's birth date).
In total 4 blood samples are to be collected. In the primary vaccination period, blood samples are to be collected before the first primary vaccination (D01) and 30 days post the 3rd dose of primary vaccination (D151); in the booster vaccination period, blood samples are to be collected before booster vaccination at V05 and 30 days post booster vaccination (V06).
Telephone calls are planned on the 4th, the 9th, and the 21st day after each vaccination (including the booster dose), and 5 TCs (1 TC/month) are planned for the 5 months post the last on-site visit of the primary and the booster vaccination periods (ie, V04 and V06), respectively, for safety follow-up. A safety visit is planned on the 9th day after the first vaccination for the ESDR participants (the first 30 participants in this group).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
2 doses of MenACYW conjugate vaccine to participants aged 12 through 23 MoA
Biological: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA)
2 doses of MenACYW135, CanSino conjugate vaccine to participants aged 12 through 23 MoA
Biological: Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China)
2-dose primary vaccination and 1-dose booster of MenACYW conjugate vaccine to participants aged 6 through 11 MoA
Biological: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA)
2-dose primary vaccination and 1-dose booster of MenACYW135, CanSino conjugate vaccine to participants aged 6 through 11 MoA
Biological: Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China)
3-dose primary vaccination and 1-dose booster of MenACYW conjugate vaccine to participants aged 3 through 5 MoA
Biological: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA)
3-dose primary vaccination and 1-dose booster of MenACYW135, CanSino conjugate vaccine to participants aged 3 through 5 MoA
Biological: Menhycia® (ACYW135 Meningococcal Conjugate Vaccine [CRM197]) (CanSino Biologics Inc., China)
3-dose primary vaccination and 1-dose booster of MenACYW conjugate vaccine to participants aged 2 MoA
Biological: MenQuadfi® (Meningococcal Polysaccharide [Serogroups A, C, W, and Y] Tetanus Toxoid Conjugate Vaccine) (Sanofi Pasteur Inc., Swiftwater, PA, USA)
Pharmaceutical form:Liquid solution-Route of administration:IM injection
Pharmaceutical form:Lyophilized powder (MenAC conjugate vaccine) and liquid solution (MenYW135 conjugate vaccine)-Route of administration:IM injection
Participants 12 through 23 MoA (Cohort I): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W
30 days post-2nd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-2nd vaccination for participants with pre-vaccination rSBA titer ≥1:8
Time frame: 30 days post 2nd vaccination (up to Day 121)
Participants 12 through 23 MoA (Cohort I): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W measured by rSBA
30 days (+10 days) post-2nd vaccination with MenACYW conjugate vaccine or MenACYW135, CanSino conjugated vaccine
Time frame: 30 days post 2nd vaccination (up to Day 121)
Participants 6 through 11 MoA (Cohort II): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W
30 days post-2nd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-2nd vaccination for participants with pre-vaccination rSBA titer ≥1:8
Time frame: 30 days post 2nd vaccination (up to Day 121)
Participants 6 through 11 MoA (Cohort II): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA
30 days (+10 days) post-2nd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugated vaccine
Time frame: 30 days post 2nd vaccination (up to Day 121)
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W
30 days post-3rd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-3rd vaccination for participants with pre-vaccination rSBA titer ≥1:8
Time frame: Day 91
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA
30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine
Time frame: Day 91
Participants 2 through 5 MoA (Cohort III - Groups 7 and 6): Vaccine seroresponse to meningococcal serogroups A, C, Y, and W
30 days post-3rd vaccination rSBA titer ≥1:8 for participants with pre-vaccination rSBA titer \<1:8, or At least 4-fold increase in rSBA titer from pre- to 30 days post-3rd vaccination for participants with pre-vaccination rSBA titer ≥1:8
Time frame: Day 151
Participants 2 through 5 MoA (Cohort III - Groups 7 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA
30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine (Group 7) or MenACYW135, CanSino conjugate vaccine (Group 6)
Time frame: Day 151
Number of participants with immediate adverse events (AEs)
Unsolicited systemic AEs that occur within 30 minutes after vaccination
Time frame: Within 30 minutes post-vaccination
Presence of solicited injection site reactions
(pre-listed in the participant diary and CRF)
Time frame: for 8 days, including the day of each study vaccination.
Presence of solicited systemic reactions
(pre-listed in the participant diary and CRF)
Time frame: for 8 days, including the day of each study vaccination.
Presence of unsolicited AEs
Time frame: for 30 days including the day of each study vaccination.
Presence of SAEs
Time frame: Approximately 7 months to 9 months for Group 1 and Group 2; up to 18 months for participants from Group 3 and Group 4; up to 21◦months for participants from Group 5 and Group 6; Approximately 16 months for participants from Group 7
Presence of AEs leading to study discontinuation
Time frame: Approximately 7 months to 9 months for Group 1 and Group 2; up to 18 months for participants from Group 3 and Group 4; up to 21◦months for participants from Group 5 and Group 6; Approximately 16 months for participants from Group 7
Participants 12 through 23 MoA (Cohort I) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA 30 days (+10 days) post-2nd vaccination with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine.
Time frame: 30 days post 2nd vaccination (up to Day 121)
Participants 6 through 11 MoA (Cohort II) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA
30 days (+10 days) post-2nd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugated vaccine.
Time frame: 30 days post 2nd vaccination (up to Day 121)
Participants 6 through 11 MoA (Cohort II) Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA pre-booster dose at 18 MoA.
Time frame: at 18 MoA (up to Day 394)
Participants 6 through 11 MoA (Cohort II) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA pre-booster dose at 18 MoA
Time frame: at 18 MoA (up to Day 394)
Participants 6 through 11 MoA (Cohort II) Antibody titers (in terms of GMTs) against booster meningococcal serogroups A, C, Y, and W, measured by rSBA 30 days (+10 days) post-booster vaccination with MenACYW conjugate vaccine given at 18 MoA.
Time frame: at 18 MoA (up to Day 424)
Participants 6 through 11 MoA (Cohort II) Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA 30 days (+10 days) after one dose of booster vaccination of MenACYW conjugate vaccine
Time frame: at 18 MoA (up to Day 424)
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA
30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine.
Time frame: D91
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA
pre-booster dose at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine
Time frame: at 12 and 18 MoA (up to Day 484)
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA
pre-booster dose at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine
Time frame: at 12 and 18 MoA (up to Day 484)
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA
30 days (+10 days) post-booster vaccination at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine
Time frame: 30 days after 12 and 18 MoA (up to Day 514)
Participants 3 through 5 MoA (Cohort III -Groups 5 and 6): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA
30 days (+10 days) post-booster vaccination at 12 and 18 MoA with MenACYW conjugate vaccine or MenACYW135, CanSino conjugate vaccine
Time frame: 30 days after 12 and 18 MoA (up to Day 514)
Participants 2 MoA (Cohort III - Group 7): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W measured by rSBA 30 days (+10 days) post-3rd vaccination of the primary series with MenACYW conjugate vaccine (Group 7).
Time frame: D151
Participants 2 MoA (Cohort III - Group 7): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA pre-booster dose at 12 MoA (Group 7) with MenACYW conjugate vaccine
Time frame: at 12 MoA (up to Day 333)
Participants 2 MoA (Cohort III - Group 7): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA pre-booster dose at 12 MoA (Group 7) with MenACYW conjugate vaccine
Time frame: at 12 MoA (up to Day 333)
Participants 2 MoA (Cohort III - Group 7): Antibody titers (in terms of GMTs) against meningococcal serogroups A, C, Y, and W, measured by rSBA 30 days (+10 days) post-booster vaccination with MenACYW conjugate vaccine at 12 MoA (Group 7)
Time frame: 30 days after 12 MoA (up to Day 363)
Participants 2 MoA (Cohort III - Group 7): Antibody titers ≥1:8 and ≥1:128 against meningococcal serogroups A, C, Y, and W, measured by rSBA 30 days (+10 days) post-booster vaccination with MenACYW conjugate vaccine at 12 MoA (Group 7)
Time frame: 30 days after 12 MoA (up to Day 363)
Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Started Aug 2026 (actual). Primary completion is estimated for Mar 2028, 18 months after the start.
Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's planned 18 months is above that.
Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.